{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:17:09Z","timestamp":1783016229840,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025815","name":"Ulman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM147005"],"award-info":[{"award-number":["R35GM147005"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jchromb.2025.124713","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T23:18:41Z","timestamp":1750807121000},"page":"124713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comprehensive pharmacokinetics and ADME evaluation of Akuamma alkaloids"],"prefix":"10.1016","volume":"1263","author":[{"given":"Abhishek","family":"Gour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M.","family":"Creed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhisheak","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124713_bb0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2025.124713_bb0010","article-title":"The opioid epidemic: a review of the contributing factors, negative consequences, and best practices","volume":"15","author":"Judd","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jchromb.2025.124713_bb0015","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.jchromb.2025.124713_bb0020","first-page":"385","article-title":"Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications, future","volume":"6","author":"Vardanyan","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124713_bb0025","first-page":"97","article-title":"Fourth wave of opioid (illicit drug) overdose deaths and diminishing access to prescription opioids and interventional techniques: cause and effect","volume":"25","author":"Manchikanti","year":"2022","journal-title":"Pain Physician"},{"key":"10.1016\/j.jchromb.2025.124713_bb0030","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1021\/acs.jmedchem.1c01273","article-title":"A novel mitragynine analog with low-efficacy mu opioid receptor agonism displays antinociception with attenuated adverse effects","volume":"64","author":"Chakraborty","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124713_bb0035","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1523\/JNEUROSCI.3723-08.2009","article-title":"Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization","volume":"29","author":"Virk","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jchromb.2025.124713_bb0040","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors\u2013improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jchromb.2025.124713_bb0045","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2017.07.002","article-title":"Mu-opioid receptor biased ligands: a safer and painless discovery of analgesics?","volume":"22","author":"Madariaga-Maz\u00f3n","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jchromb.2025.124713_bb0050","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/AJP.0b013e3181c49e3a","article-title":"Delta and kappa opioid receptors as suitable drug targets for pain","volume":"26","author":"Vanderah","year":"2010","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.jchromb.2025.124713_bb0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.lfs.2005.09.006","article-title":"Analgesic substances derived from natural products (natureceuticals)","volume":"78","author":"McCurdy","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.jchromb.2025.124713_bb0060","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/acs.biochem.0c00629","article-title":"Natural products for the treatment of pain: chemistry and pharmacology of salvinorin a, mitragynine, and collybolide","volume":"60","author":"Chakraborty","year":"2020","journal-title":"Biochem"},{"key":"10.1016\/j.jchromb.2025.124713_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.801855","article-title":"Understanding kratom use: a guide for healthcare providers","volume":"13","author":"Swogger","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2016","key":"10.1016\/j.jchromb.2025.124713_bb0070","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jchromb.2025.124713_bb0075","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1360-0443.2008.02209.x","article-title":"Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)","volume":"103","author":"Boyer","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.jchromb.2025.124713_bb0080","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s13181-018-0685-1","article-title":"Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity","volume":"14","author":"Toce","year":"2018","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.jchromb.2025.124713_bb0085","first-page":"1","article-title":"Evaluation of naturally occurring opioids and synthetic derivatives for therapeutic application in alcohol abuse and pain","author":"Gutridge","year":"2021","journal-title":"Diss. Purdue Univ."},{"key":"10.1016\/j.jchromb.2025.124713_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1995-7645(13)60182-0","article-title":"Medicinal uses, phytochemistry and pharmacology of Picralima nitida (Apocynaceae) in tropical diseases: a review","volume":"7","author":"Erharuyi","year":"2014","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.jchromb.2025.124713_bb0095","first-page":"71","article-title":"Chronic oral consumption of ethanolic extract of Picralima nitida (akuamma) seed induced histopathological changes on the testes of adult Wistar rats","volume":"3","author":"Solomon","year":"2014","journal-title":"Int. J. Pharm. Res. Allied Sci."},{"key":"10.1016\/j.jchromb.2025.124713_bb0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/acs.jnatprod.0c01036","article-title":"Isolation and pharmacological characterization of six opioidergic Picralima nitida alkaloids","volume":"84","author":"Creed","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.jchromb.2025.124713_bb0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jep.2014.01.027","article-title":"Picralima nitida seeds suppress PGE2 production by interfering with multiple signalling pathways in IL-1\u03b2-stimulated SK-N-SH neuronal cells","volume":"152","author":"Olajide","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jchromb.2025.124713_bb0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0378-8741(02)00058-2","article-title":"Pseudo-akuammigine, an alkaloid from Picralima nitida seeds, has anti-inflammatory and analgesic actions in rats","volume":"81","author":"Duwiejua","year":"2002","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jchromb.2025.124713_bb0115","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1021\/acs.jmedchem.2c01707","article-title":"Modified akuamma alkaloids with increased potency at the mu-opioid receptor","volume":"66","author":"Hennessy","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124713_bb0120","first-page":"1","article-title":"Antioxidant and glycemic potentials of the flesh, seeds, peels and the whole fruit of Picralima nitida","volume":"1","author":"Agbaje","year":"2024","journal-title":"Adv. Environ. Health Sci. Toxicol."},{"key":"10.1016\/j.jchromb.2025.124713_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41110-024-00309-z","article-title":"The crude alkaloidal extract of Picralima nitida seeds alleviates TNBS-induced inflammatory bowel disease through reduced serum expression of TNF-\u03b1, IL-1\u03b2 and p38 MAPK","volume":"50","author":"Otu-Boakye","year":"2024","journal-title":"Nutrire"},{"key":"10.1016\/j.jchromb.2025.124713_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.855","article-title":"Acetic acid-induced colitis modulating potential of total crude alkaloidal extract of Picralima nitida seeds in rats","volume":"11","author":"Otu-Boakye","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.jchromb.2025.124713_bb0135","unstructured":"Center for Drug Evaluation and Research, United States Food and Drug Administration. Bioanalytical Method Validation: Guidance for Industry. US Department of Health and Human Services, (2018). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry (accessed 11 April 2025)."},{"key":"10.1016\/j.jchromb.2025.124713_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/dta.3703","article-title":"Preclinical pharmacokinetic studies of villocarine a, an active Uncaria alkaloid","volume":"17","author":"Chiang","year":"2025","journal-title":"Drug Test Anal."},{"key":"10.1016\/j.jchromb.2025.124713_bb0145","doi-asserted-by":"crossref","first-page":"32637","DOI":"10.1021\/acsomega.1c04266","article-title":"Pharmacokinetic assessment of rottlerin from Mallotus philippensis using a highly sensitive liquid chromatography\u2013tandem mass spectrometry-based bioanalytical method","volume":"6","author":"Manhas","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.jchromb.2025.124713_bb0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","article-title":"Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids","volume":"63","author":"Obeng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124713_bb0155","first-page":"1316","article-title":"Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans","volume":"29","author":"Naritomi","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2025.124713_bb0160","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/a-0770-3683","article-title":"Comparative pharmacokinetics of mitragynine after oral administration of Mitragyna speciosa (kratom) leaf extracts in rats","volume":"85","author":"Avery","year":"2019","journal-title":"Planta Med."},{"key":"10.1016\/j.jchromb.2025.124713_bb0165","series-title":"Prediction of Human Pharmacokinetics","first-page":"127","author":"Khojasteh","year":"2011"},{"key":"10.1016\/j.jchromb.2025.124713_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jchromb.2025.124713_bb0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1208\/s12248-022-00736-8","article-title":"Metabolism of speciociliatine, an overlooked kratom alkaloid for its potential pharmacological effects","volume":"24","author":"Kamble","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.jchromb.2025.124713_bb0180","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/med.1016","article-title":"Role of drug metabolism in drug discovery and development","volume":"21","author":"Kumar","year":"2001","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jchromb.2025.124713_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17460441.2.1.51","article-title":"The importance of plasma protein binding in drug discovery","volume":"2","author":"Trainor","year":"2007","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jchromb.2025.124713_bb0190","doi-asserted-by":"crossref","first-page":"446P","DOI":"10.1111\/j.1365-2125.1978.tb04617.x","article-title":"Protein binding of atenolol and propranolol to human serum albumin and in human plasma [proceedings]","volume":"6","author":"Barber","year":"1978","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:45:40Z","timestamp":1751427940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S1570023225002673"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124713","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive pharmacokinetics and ADME evaluation of Akuamma alkaloids","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124713"}}